Max Planck, AiCuris Launch Antibacterial Collaboration

The Max Planck Institute of Molecular Physiology (MPI) and AiCuris said today they will partner to discover new antibacterial drugs to treat viral and bacterial infections, through a collaboration whose value was not disclosed.AiCuris will gain access to MPI’s proprietary collection of natural product-based compounds. The company will join researchers led by Herbert Waldmann, Ph.D., director of MPI’s chemical biology department, to investigate and optimize compounds that are found to